InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,217.39
(
0.06%
)
US TECH 100
17,674.00
(
0.19%
)
Dow Jones
39,456.54
(
0.17%
)
Brent Oil
82.73
(
-1.46%
)
Bitcoin
60,544.40
(
-3.97%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Whosetosay

Send PM Follow Ignore
Followers 26
Posts 4429
Boards Moderated 0
Alias Born 06/08/2010

Whosetosay

Re: None

Thursday, 10/23/2014 7:01:01 PM

Thursday, October 23, 2014 7:01:01 PM

Post# of 80490
As one considers the challenges facing Ponatinib, and the upward path of '113, this company could give '113 the mantle of flagship product. If the '113 trials continue well, and criz failures continue at the 50% rate after a year, '113 would reach the $500M mark well ahead of Pona.

Still, big "if", and mN has to be a winner. and Pona needs to make some improvement for the company to stay independent. Tall order. Sadly, Pona's AE's will likely forever relegate it to 'last line' status, and Ariad should price it according ly.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up